NCT01281462 - Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections | Biotech Hunter

Enrollment

217

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

July 31, 2012

Conditions

Urinary Tract Infections

Interventions

DRUG

Ceftaroline fosamil and NXL104 (q8h)

600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 8 hours (q8h);

DRUG

Ceftaroline fosamil and NXL104 (q12h)

600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 12 hours (q12h);

DRUG

Doripenem

500 mg doripenem IV q8h;

DRUG

Placebo

On CXL-MD-02, there were (3) treatment arms (meaning a subject could be randomized to 1 of 3 possible treatment regimens). Each treatment arm contained 1 or 2 placebo doses of IV saline in order to preserve the blind.

Trial Locations (50)

1407

Investigational Site, Sofia

1431

Investigational Site, Sofia

1606

Investigational Site, Sofia

4002

Investigational Site, Plovdiv

7002

Investigational Site, Rousse

9002

Investigational Site, Varna

10117

Investigational Site, Berlin

21280

Investigational Site, Diyarbakır

21287

Investigational Site, Baltimore

26480

Investigational Site, Eskişehir

32429

Investigational Site, Minden

32504

Investigational Site, Pensacola

33098

Investigational Site, Paderborn

34125

Investigational Site, Kassel

35040

Investigational Site, Izmir

35340

Investigational Site, Izmir

35385

Investigational Site, Giessen

48202

Investigational Site, Detroit

79106

Investigational Site, Freiburg im Breisgau

79379

Investigational Site, Müllheim

82152

Investigational Site, Planegg

91942

Investigational Site, La Mesa

92120

Investigational Site, San Diego

105077

Investigational Site, Moscow

105425

Investigational Site, Moscow

111123

Investigational Site, Moscow